Brian Cahill's most recent trade in Eagle Pharmaceuticals Inc was a trade of 3,800 Common Stock done . Disclosure was reported to the exchange on Feb. 27, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | Brian Cahill | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 3,800 | 49,547 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Cahill Brian | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.44 per share. | 27 Feb 2024 | 1,589 | 47,958 (0%) | 0% | 6.4 | 10,233 | Common Stock |
| Eagle Pharmaceuticals Inc | Cahill Brian | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.85 per share. | 02 Feb 2024 | 934 | 45,747 (0%) | 0% | 5.9 | 5,464 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. | 05 Jan 2024 | 735 | 46,681 (0%) | 0% | 5.1 | 3,771 | Common Stock |
| Eagle Pharmaceuticals Inc | Cahill Brian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 18 Dec 2023 | 452 | 47,416 (0%) | 0% | 4.8 | 2,152 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 18,500 | 47,868 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.00 per share. | 28 Feb 2023 | 718 | 29,368 (0%) | 0% | 28 | 20,104 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.09 per share. | 02 Feb 2023 | 785 | 30,086 (0%) | 0% | 34.1 | 26,761 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.21 per share. | 30 Jan 2023 | 601 | 30,871 (0%) | 0% | 33.2 | 19,959 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.26 per share. | 05 Jan 2023 | 734 | 31,472 (0%) | 0% | 29.3 | 21,477 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.03 per share. | 19 Dec 2022 | 461 | 32,206 (0%) | 0% | 30.0 | 13,844 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 8,000 | 32,667 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.03 per share. | 02 Feb 2022 | 805 | 24,667 (0%) | 0% | 45.0 | 36,249 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.94 per share. | 31 Jan 2022 | 626 | 25,472 (0%) | 0% | 45.9 | 28,758 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.63 per share. | 07 Jan 2022 | 263 | 26,098 (0%) | 0% | 50.6 | 13,316 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.69 per share. | 05 Jan 2022 | 738 | 26,361 (0%) | 0% | 50.7 | 37,409 | Common Stock |